Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cilastatin Sodium

FDA-approved product (powder, intravenous).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Cilastatin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Endocarditis
  • Infection
  • Pneumonia
  • Sepsis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

Anti-infective classification
Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.

Repurposing investigation

Cilastatin Sodium reaches ≥40% AI-predicted activity against M. tuberculosis, but no WHO ATC code or FDA pharmacologic class says whether it is already an antimicrobial. It needs review, so it is not counted among the repurposing candidates.

AI-predicted activity

AI prediction · nothing measured
  • MRSA28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli27.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis41.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cilastatin Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cilastatin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver Transplantation

    NCT07759453 · start 2026-10-01

    Registered record
    Registry ID
    NCT07759453
    Conditions
    Liver Transplant; Carbapenem-resistant Enterobacterales; CRE Colonization
    Interventions
    Ceftazidime - Avibactam ( CAZ-AVI); Meropenem-Vaborbactam; Imipenem+Relebactam; Cefiderocol; Aztreonam; Eravacycline; Aztreonam-Avibactam; Amoxi Clavulanate; Piperacillin + Tazobactam; Tigecycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2029-09-30
    Enrolment
    168

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplant; Carbapenem-resistant Enterobacterales; CRE Colonization
    InterventionCeftazidime - Avibactam ( CAZ-AVI); Meropenem-Vaborbactam; Imipenem+Relebactam; Cefiderocol +6 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection

    NCT07228702 · start 2026-01-11

    Registered record
    Registry ID
    NCT07228702
    Conditions
    Non-Tuberculous Mycobacterial (NTM) Pneumonia; Mycobacterium Abscessus Infection
    Interventions
    Mycobacteriophage Muddy_HRMN0052; Amikacin Injection; Clofazimine; Bedaquiline (B); Linezolid (LZD); Sulfamethoxazole/Trimethoprim; Imipenem + Cilastatin; Ceftaroline fosamil; Omadacycline Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Enrolling by invitation
    Start
    2026-01-11
    Completion
    2027-10
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Tuberculous Mycobacterial (NTM) Pneumonia; Mycobacterium Abscessus Infection
    InterventionMycobacteriophage Muddy_HRMN0052; Amikacin Injection; Clofazimine; Bedaquiline (B) +5 more
    PhasePhase 1
    Registry statusEnrolling by invitation

  • Prevention of Nephrotoxin-Induced Acute Kidney Injury Using Cilastatin

    NCT06886464 · start 2025-07-16

    Registered record
    Registry ID
    NCT06886464
    Conditions
    Acute Kidney Injury
    Interventions
    Cilastatin Sodium; Placebo-Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-07-16
    Completion
    2029-12
    Enrolment
    698

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Kidney Injury
    InterventionCilastatin Sodium; Placebo-Saline
    PhasePhase 2
    Registry statusRecruiting

  • A Double-blind Non Inferiority Clinical Trial to Compare the Nephroprotection of Cilastatn Versus Thiosulfate in Patients Undergoing Debulking Surgery With Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Cisplatin.

    NCT07229040 · start 2025-02-21

    Registered record
    Registry ID
    NCT07229040
    Conditions
    Debulking Surgery for Ovarian Cancer; Acute Kidney Injury
    Interventions
    cilastatine; tiosulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-02-21
    Completion
    2028-10-21
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDebulking Surgery for Ovarian Cancer; Acute Kidney Injury
    Interventioncilastatine; tiosulfate
    PhasePhase 2
    Registry statusRecruiting

  • A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

    NCT06569056 · start 2024-09-25

    Registered record
    Registry ID
    NCT06569056
    Conditions
    Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
    Interventions
    HRS-8427; Imipenem and Cilastatin Sodium; HRS-8427 placebo; Imipenem and Cilastatin Sodium placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-09-25
    Completion
    2025-11
    Enrolment
    578

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
    InterventionHRS-8427; Imipenem and Cilastatin Sodium; HRS-8427 placebo; Imipenem and Cilastatin Sodium placebo
    PhasePhase 3
    Registry statusRecruiting

  • A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

    NCT06059846 · start 2023-12-21

    Registered record
    Registry ID
    NCT06059846
    Conditions
    Urinary Tract Infection; Acute Pyelonephritis
    Interventions
    TBP-PI-HBr; Imipenem-cilastatin; Dummy Infusion; Dummy Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-12-21
    Completion
    2025-02-06
    Enrolment
    1,690

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infection; Acute Pyelonephritis
    InterventionTBP-PI-HBr; Imipenem-cilastatin; Dummy Infusion; Dummy Tablets
    PhasePhase 3
    Registry statusCompleted

  • A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis

    NCT06144060 · start 2023-12

    Registered record
    Registry ID
    NCT06144060
    Conditions
    Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
    Interventions
    HRS -8427; Imipenem and Cilastatin Sodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-12
    Completion
    2024-07
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
    InterventionHRS -8427; Imipenem and Cilastatin Sodium
    PhasePhase 2
    Registry statusUnknown

  • The Effect of the Care Bundle to be Applied to Obesity Surgery Patients on Surgical Site Infection and Patient Comfort

    NCT05930639 · start 2023-06-12

    Registered record
    Registry ID
    NCT05930639
    Conditions
    Bariatric Surgery Candidate
    Interventions
    Surgical Site Infection (SSI) prevention package
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-06-12
    Completion
    2023-10
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBariatric Surgery Candidate
    InterventionSurgical Site Infection (SSI) prevention package
    PhaseNot applicable
    Registry statusUnknown

  • Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis

    NCT05887908 · start 2023-05-23

    Registered record
    Registry ID
    NCT05887908
    Conditions
    Complicated Urinary Tract Infection; Acute Pyelonephritis; cUTI; AP
    Interventions
    co-administration of cefepime and nacubactam; co-administration of aztreonam and nacubactam; imipenem/cilastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-05-23
    Completion
    2024-11-26
    Enrolment
    614

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Urinary Tract Infection; Acute Pyelonephritis; cUTI; AP
    Interventionco-administration of cefepime and nacubactam; co-administration of aztreonam and nacubactam; imipenem/cilastatin
    PhasePhase 3
    Registry statusCompleted

  • Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)

    NCT05204368 · start 2023-03-30

    Registered record
    Registry ID
    NCT05204368
    Conditions
    Complicated Urinary Tract Infection Including Acute Pyelonephritis
    Interventions
    Combination of Imipenem/Cilastatin and XNW4107; Meropenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2023-03-30
    Completion
    2025-12
    Enrolment
    780

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Urinary Tract Infection Including Acute Pyelonephritis
    InterventionCombination of Imipenem/Cilastatin and XNW4107; Meropenem
    PhasePhase 3
    Registry statusUnknown

  • Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis

    NCT05561764 · start 2023-01-03

    Registered record
    Registry ID
    NCT05561764
    Conditions
    Cystic Fibrosis; Pneumonia, Bacterial
    Interventions
    Imipenem/Cilastatin/Relebactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2023-01-03
    Completion
    2024-12-11
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis; Pneumonia, Bacterial
    InterventionImipenem/Cilastatin/Relebactam
    PhasePhase 4
    Registry statusTerminated

  • Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients

    NCT05146154 · start 2023-01-01

    Registered record
    Registry ID
    NCT05146154
    Conditions
    Obesity; Critical Illness
    Interventions
    Imipenem/Cilastatin/Relebactam 1.25g
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2023-01-01
    Completion
    2024-01-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity; Critical Illness
    InterventionImipenem/Cilastatin/Relebactam 1.25g
    PhasePhase 4
    Registry statusWithdrawn

  • Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)

    NCT05204563 · start 2022-07-31

    Registered record
    Registry ID
    NCT05204563
    Conditions
    Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
    Interventions
    Combination of Imipenem/Cilastatin and XNW4107; Imipenem/Cilastatin/Relebactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-07-31
    Completion
    2024-09-29
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
    InterventionCombination of Imipenem/Cilastatin and XNW4107; Imipenem/Cilastatin/Relebactam
    PhasePhase 3
    Registry statusCompleted

  • PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

    NCT04983901 · start 2021-09-14

    Registered record
    Registry ID
    NCT04983901
    Conditions
    Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm
    Interventions
    Imipenem/Cilastatin/Relebactam; Cefepime; Meropenem; Piperacillin-Tazobactam; Vancomycin; Daptomycin; Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-09-14
    Completion
    2023-10-06
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm
    InterventionImipenem/Cilastatin/Relebactam; Cefepime; Meropenem; Piperacillin-Tazobactam +3 more
    PhasePhase 2
    Registry statusCompleted

  • Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections

    NCT04785924 · start 2021-06-07

    Registered record
    Registry ID
    NCT04785924
    Conditions
    Carbapenem-Resistant Enterobacteriaceae Infection; KPC; Gram-Negative Bacterial Infections; Antibiotic Resistant Infection
    Interventions
    Imipenem+Relebactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2021-06-07
    Completion
    2023-01-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarbapenem-Resistant Enterobacteriaceae Infection; KPC; Gram-Negative Bacterial Infections; Antibiotic Resistant Infection
    InterventionImipenem+Relebactam
    PhasePhase 4
    Registry statusWithdrawn